Cooverexpression of EpCAM and c-myc genes in malignant breast tumours
The overexpression of epithelial cell adhesion molecule (EpCAM), a proto-oncogene, affects progression, treatment, and diagnosis of many adenocarcinomas. C-myc has been shown to be a downstream target of EpCAM and is also one of the most important proto-oncogenes routinely overexpressed in breast cancer. However, cooverexpression of EpCAM and c-myc genes has not been investigated in breast cancer tissues, particularly in Iranian population. The aim of this study was to assess the expression of EpCAM and c-myc genes in malignant breast cancer tissues using reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) followed by analyses of the association between the outcomes. In this study, 122 fresh tissues, including 104 malignant and 18 benign samples, were disrupted by mortar and pestle, and then the RNA was isolated from the samples and converted to cDNA. The relative expression levels of EpCAM and c-myc genes were measured by 2 −ΔΔCt method using RT-qPCR. EpCAM protein level was also assessed in 66 cases using Western blot technique. Using RT-qPCR method, our results showed that EpCAM was overexpressed in 48% of malignant and 11.1% of benign samples. Evaluating EpCAM protein overexpression in a portion of samples depicted the fully concordance rate between Western blot and RT-qPCR techniques. C-myc expression was first evaluated by RT-qPCR method, showing the overexpression rate of 39% and 28% in malignant and benign samples, respectively. These data were also quite concordant with the clinically available immunohistochemistry reports of the same samples studied in this study. Importantly, overexpression of EpCAM and c-myc was significantly associated and showed an agreement of 57.3%. This study demonstrated the cooverexpression of EpCAM and c-myc in breast tumours collected from breast cancer patients of the Iranian population. EpCAM and c-myc positive cases were significantly associated with reduced and enhanced risk of ER/PR positivity respectively. However, both were associated with grade III of breast cancer.
Keywordsbreast cancer c-myc gene epithelial cell adhesion molecule real-time reverse transcriptase polymerase chain reaction Western blot
This study was performed at the University of Isfahan and financially supported by the Graduate Office of the University of Isfahan. We also sincerely appreciate Dr Maryam Tabatabaeian and Dr Mehri Faghighy and Mr Nihar Masurkar for their comprehensive assistance in collecting the samples, follow up information and editions.
- Ambrogi F., Fornili M., Alberti S., Querzoli P., Piantelli M., Pedriali M. et al. 2012 EpCAM expression is an indicator of increased incidence of relapse in p53-positive breast cancer. Cancer Clin. Oncol. 2, p40.Google Scholar
- de Boer C. J., van Krieken J. H., Janssen-van Rhijn C. M. and Litvinov S. V. 1999 Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J. Pathol. 188, 201–206.Google Scholar
- Göitlinger H. G., Funke I., Johnson J. P., Gokel J. M. and Riethmüller G. 1986 The epithelial cell surface antigen 17–1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int. J. Cancer 38, 47–53.CrossRefGoogle Scholar
- Lê M. G., Mathieu M. C., Douc-Rasy S., Le Bihan M. L., Adb El All H., Spielmann M. et al. 1999 c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int. J. Cancer 84, 562–567.CrossRefPubMedGoogle Scholar
- Lutz W., Leon J. and Eilers M. 2002 Contributions of Myc to tumorigenesis. Biochim. et Biophys. Acta 1602, 61–71.Google Scholar
- Munz M., Fellinger K., Hofmann T., Schmitt B. and Gires O. 2007 Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM. Front Biosci. 13, 5195–5201.Google Scholar
- Niemiec J. A., Adamczyk A., Malecki K., Majchrzyk K. and Rys J. 2012 Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer. Appl. Immunohistochem. Mol. Morphol. 20, 550–560.CrossRefPubMedGoogle Scholar
- Scorilas A., Trangas T., Yotis J., Pateras C. and Talieri M. 1999 Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br. J. Cancer 81, 1385.CrossRefPubMedPubMedCentralGoogle Scholar
- Spandidos D., Pintzas A., Kakkanas A., Yiagnisis M., Mahera H., Patra E. et al. 1986 Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res. 7, 1299–1304.Google Scholar
- Tanida S., Mizoshita T., Ozeki K., Tsukamoto H., Kamiya T., Kataoka H. et al. 2012 Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int. J. Surg. Oncol. 2012, 280–288.Google Scholar
- van der Gun B. T., Melchers L. J., Ruiters M. H, de Leij L. F., McLaughlin P. M. and Rots M. G. 2010 EpCAM incarcinogenesis: the good, the bad or the ugly. Carcinogenesis 31, 1913–1921.Google Scholar
- Winter M. J., Nagtegaal I. D., Van Krieken J. and Litvinov S. V. 2003 The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am. J. Pathol. 163, 2139–2148.Google Scholar